2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith(Queensland Health), Martine Piccart(Université Libre de Bruxelles), José Baselga(Novartis (Switzerland)), David Cameron(Corewell Health), Robert L. Coleman(Texas Oncology), Sébastien Guillaume(Institut Jules Bordet), Nadia Harbeck(Breast Center), A. Feyereislova(Roche (Switzerland)), Richard D. Gelber(Harvard University), Mitch Dowsett(Institute of Cancer Research), Nicholas Wilcken(Westmead Hospital), Pedro Sánchez‐Rovira(Complejo Hospitalario de Jaén), Andrew Wardley(UK Research and Innovation), Marion Procter(Frontier Agriculture (United Kingdom)), Karen A. Gelmon(University of British Columbia), Jonas Bergh(Karolinska Institutet), Richard H. Bell(Geelong Hospital), Gabriella Mariani(Fondazione IRCCS Istituto Nazionale dei Tumori), Erik Wist(Oslo University Hospital), Manfred Kaufmann(Goethe University Frankfurt), Aron Goldhirsch(Istituti di Ricovero e Cura a Carattere Scientifico), Peter Mallmann(University of Cologne), R.I. Lopez(National Oncologic Institute), Michael Untch(Helios Kliniken)
Cited by 1,511
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k